Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome (Q42490093)

1 November 2017

Hypothalamic dopaminergic tone and prolactin bioactivity in women with polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

1 November 2017

1 reference

1 reference

1 reference

3

1 reference

1 November 2017

Hernández I

1

1 reference

1 November 2017

Parra A

2

1 reference

1 November 2017

Cabrera V

4

1 reference

1 November 2017

Cravioto MC

5

1 reference

1 November 2017

Mercado M

6

1 reference

1 November 2017

Díaz-Sánchez V

7

1 reference

1 November 2017

Larrea F

8

1 reference

1 November 2017

language of work or name

1 reference

1 March 2000

1 reference

Archives of Medical Research

1 November 2017

1 reference

1 November 2017

31

1 reference

1 November 2017

2

1 reference

1 November 2017

216-222

1 reference

Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis

1 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Elevated bioactive luteinizing hormone in women with the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

A preponderance of basic luteinizing hormone (LH) isoforms accompanies inappropriate hypersecretion of both basal and pulsatile LH in adolescents with polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Is polycystic ovary syndrome a neuroendocrine or an ovarian disorder?

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Increased luteinizing hormone sensitivity to dopamine inhibition in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Effects of dopamine infusion on pituitary hormone secretion in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Bromocriptine treatment of women with clomiphene-resistant polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Hyperprolactinemia in polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Evidence for altered catecholamine metabolism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Prolactin (in vitro) decreases the glucose stimulation threshold, enhances insulin secretion, and increases dye coupling among islet B cells

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Role of prolactin versus growth hormone on islet B-cell proliferation in vitro: implications for pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Insulin sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance or mild gestational diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Decreased sensitivity to insulin in women with microprolactinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Detection of Functional Ovarian Hyperandrogenism in Women with Androgen Excess

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Hypergonadotrophic hypogonadism in an XX female subject due to 17,20 steroid desmolase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

A new sensitive and specific bioassay for lactogenic hormones: measurement of prolactin and growth hormone in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

A bioactive 60-kilodalton prolactin species is preferentially secreted in cultures of mitogen-stimulated and nonstimulated peripheral blood mononuclear cells from subjects with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Effects of body weight on responses of serum prolactin to metoclopramide and thyrotrophin-releasing hormone in secondary amenorrhoeic women

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Secretory dynamics of bioactive and immunoreactive prolactin in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Evidence of altered dopaminergic modulation of prolactin and thyrotropin secretion in patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

The role of endogenous opiates in LH secretion during the menstrual cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Acute dopaminergic blockade augments the naloxone-induced LH rise in estrogen-treated postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

D2 dopamine receptor gene and obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

Decrease of norepinephrine and preservation of acetylcholine in the hypothalamus of VMH obese rats

1 reference

https://api.crossref.org/works/10.1016%2FS0188-4409%2800%2900059-X

7 January 2021

10.1016/S0188-4409(00)00059-X

Identifiers

DOI

1 reference

1 November 2017

1 reference